The main points of the European guidelines for the prevention of cardiovascular diseases in clinical practice (a review of literature)

Close metadata

Recommended articles:

Gender differences in mental and behavioural disorders as an important stage of cardiovascular diseases prevention in young people. Russian Journal of Preventive Medicine. 2024;(3):66-71

Development and testing of new methodical approaches for predicting cardiovascular events in healthy people using machine learning technology based on the «INTEREPID» international research. Russian Journal of Preventive Medicine. 2024;(3):72-79

Colorectal cancer: incidence, risk factors, and screening. Russian Journal of Preventive Medicine. 2024;(3):93-97

Possibilities of cardiometabolic diseases prevention in women with pregnancy adverse outcomes in medical history. Russian Journal of Preventive Medicine. 2024;(3):98-103

The impact of artificial intelligence on double reading of mammograms. Russian Journal of Preventive Medicine. 2024;(5):32-37

Laboratory diagnostics of lipid metabolism disorders: modern innovations in new Russian and international recommendations. Laboratory Service. 2024;(1):20-30

To the issue of early diagnosis of malignant skin neoplasms during medical check-ups. Russian Journal of Clinical Dermatology and Venereology. 2024;(2):161-167

Relapse of primary mediastinal B-cell lymphoma with isolated central nervous system involvement: risk factors and search for personalized therapy. P.A. Herzen Journal of Oncology. 2024;(2):39-45

Promising approaches to the pathogenetic therapy of amyotrophic lateral sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):13-21

Topical application of hypotensive drugs for the prevention of intraocular pressure elevation after intravitreal injections of anti-VEGF drugs. Russian Annals of Ophthalmology. 2024;(2-2):73-79

The review deals with the new European guidelines for the main areas of prevention of cardiovascular diseases (CVD) that remain the world's leading cause of untimely death. Despite the fact that CVD mortality has decreased in most European countries, it is still high in developing countries. The development of CVD is closely related to lifestyle that includes indicators, such as physical activity, bad habits, psychosocial factors, and nutrition. The 2012 European Society of Cardiology guidelines on CVD prevention in clinical practice have changed the priorities and goals of preventive measures and corrected approaches to assessing a cardiovascular risk in patients, including young people, and assigned a great role to the characteristics of major risk factors, their correction modes, and the importance of a predominance of lifestyle modification over medicinal correction method. The issues of patient adherence to physicians' advice and the need for a multilevel prevention system at all stage of medical care and social life of society are considered.

Keywords:

cardiovascular risk

prevention

recommendations

cardiovascular risk

prevention

recommendations

Authors:

Badeĭnikova K.K.

FGBU "Gosudarstvennyĭ nauchno-issledovatel'skiĭ tsentr profilakticheskoĭ meditsiny" Minzdrava RF, Petroverigskiĭ pereulok

Mamedov M.N.

Gosudarstvennyĭ nauchno-issledovatel'skiĭ tsentr profilakticheskoĭ meditsiny, Moskva

List of references:

National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 25: 3143-3421.
The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012; 33: 1635-1701.
European Heart Network. Eur Cardiovasc Dis Stat. 2008.
Oganov R.G., Maslennikova G.Ya., Koltunov I.E., Kalinina A.M. Neobkhodimye usloviya dlya profilaktiki serdechno-sosudistykh I drugikh neinfektsionnykh zabolevaniy v Rossiyskoy Federatsii [The indispensable conditions or the prevention of cardiovascular and other non-infectious diseases in the Russian Federation]. Terap I prof 2010; 9: 6: 4-9. [In Russ.].
Starodubov V.I., Ivanova A.V., Semina V.G., et al. Zdorov'e natsii. Dinamika I prognozy zdorov'ya naseleniya Rossii v sotsial"nom kontekste 90-kh godov XX veka [The health of the nation. Dynamics and prognoses of the health status of the population of Russia in the social context in the1990s of the XXth century]. Glavvrach2002; 8: 13-32. [In Russ.].
Kalinina A.M., Pozdnyakov Yu.M., Eganyan R.A. Stabil'naya stenokardiya. Pod red. R.G. Oganova [Stable angina. Ed. R.G. Oganov]. M 2010. [In Russ.].
Bolezni Serdtsa I sosudov. Rukovodstvo Evropeiskogo obshchestva kardiologov. Pod red. A. D. Camm, Th. F. Luscher, and P. W. Serruys. Per. s angl. Pod red. E.V. Shlyakhto [The diseases of heart and vessels. The ESC Textbook of Cardiovascular Medicine. Eds. A. D. Camm, Th. F. Luscher, and P. W. Serruys. Transl. from English. Ed. E.V. Shlyakhto]. M 2011. [In Russ.].
World Health Organization. Joint WHO/FAO Expert Consultation on Diet. Nutrit Prevent Chron Dis 2002.
Puska P. Successful strategies to influence national diets: the Finnish experience. Zdrav Var 2003; 43: 191-196.
Shal'nova S.A., Kalinina A.M., Martsevich S.Yu., Karmanova N.S., Fedotova A.V. Profilaktika serdechno-sosudistykh zabolevaniy v klinicheskoy praktile [Prevention of cardiovascular diseases in clinical practice]. M 2009. [In Russ.].
Oganov R.G., Shal'nova S.A., Kalinina A.M. Profilaktika serdechno-sosudistykh zabolevaniy: rukovodstvo [Prevention of cardiovascular diseases in clinical practice: the guidelines]. M 2009. [In Russ.].
Rose G. Sick individuals and sick populations. Int J Epidemiol 1985; 14: 32-38.
Artinian N.T., Fletcher G.F., Mozaffarian D., Kris-Etherton P., Van Horn L., Lichtenstein A.H., Kumanyika S., Kraus W.E., Fleg J.L., Redeker N.S., Meininger J.C., Banks J., Stuart-Shor E.M., Fletcher B.J., Miller T.D., Hughes S., Braun L.T., Kopin L.A., Berra K., Hayman L.L., Ewing L.J., Ades P.A., Durstine J.L., Houston-Miller N., Burke L.E. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation 2010; 122: 406-441.
Piepoli M.F., Corra U., Benzer W., Bjarnason-Wehrens B., Dendale P., Gaita D., McGee H., Mendes M., Niebauer J., Zwisler A.D., Schmid J.P. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil 2010; 17: 1-17.
Prescott E., Hippe M., Schnohr P., Hein H.O., Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998; 316: 1043-1047.
Mucha L., Stephenson J., Morandi N., Dirani R. Metaanalysis of disease risk associated with smoking, by gender and intensity of smoking. Gend Med 2006; 3: 279-291.
Prescott E., Scharling H., Osler M., Schnohr P. Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study. J Epidem Com Health 2002; 56: 702-706.
Center for Disease Control and Prevention. How Tobacco Smoke Causes Disease: The Biology and Behavioural Basis for Smoking-attributable Disease. Report Surg Gen 2010.
Law M.R., Morris J.K., Wald N.J. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ 1997; 315: 973-980.
International Agency for Research on Cancer. Tobacco Control' Reversal of Risk After Quitting Smoking. IARC Handbooks of Cancer Prevention. Lyon: IARC 2007; 11.
Wu J., Ho S., Zhou C. et al. Coffee consumption and risk of coronary heart diseases: A meta-analysis of 21 prospective cohort studies. Int J Cardiol 2009; 137: 216.
Knowler W., Barrett-Connor E., Fowler S. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393.
Yakushin S., Filippov E. Profilaktika serdechno-sosudistykh zabolevaniy: kurs na zdorovy obraz zhizni [The prevention of cardiovascular diseases; toward the healthy lifestyle]. Vrach 2011; 9: 2-7. [In Russ.].
Whitlock G., Lewington S., Sherliker P., Clarke R., Emberson J., Halsey J., Qizilbash N., Collins R., Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-1096.
Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
Gradman A.H., Schmieder R.E., Lins R.L., Nussberger J., Chiang Y., Bedigian M.P. Aliskiren, a novel orally effective renin inhibitor provides dose-dependent antihypertensive efficacy placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018.
Mamedov M.N. Shkola po diagnostike I lecheniyu giperlipidemii [The school of diagnostics and treatment of hyperlipidemia]. M. 2006. [In Russ.].
Ho P.M., Bryson C.L., Rumsfeld J.S. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119: 3028-3035.

Close metadata